

SLR:dm 5 17 02 4239-62489 117475.doc

PATENT Attorney Reference Number 4239-62489

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 1 9 /007

In re application of: Hanada and Yang

Art Unit: Not yet assigned

Application No. 10/089,485

CERTIFICATE OF MAILING TECH CENTER 1600/2900

Filed: March 27, 2002

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 17, 2002, as First Class Mail in an envelope addressed to: BOX PCT.

COMMISSIONER FOR PATENTS, WASHINGTON D.C.

For: FIBROBLAST GROWTH FACTOR-5 (FGF-5) IS A TUMOR ASSOCIATED T-CELL

20231.

ANTIGEN

Examiner: Not yet assigned

Date: May 17, 2002

Agent for Applicants

TRANSMITTAL LETTER

BOX PCT COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

Revocation of Prior Power of Attorney, New Power of Attorney by Assignee and Certificate by Assignee Under 37 CFR § 3.73.

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Sheree Lynn Rybak, Pl Registration No. 47,91

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

cc: Docketing

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hanada and Yang

Art Unit: Not yet assigned

JUN 1 9 7003

Application No. 10/089,485

Filed: March 27, 2002

For: FIBROBLAST GROWTH FACTOR-5 (FGF-5)

IS A TUMOR ASSOCIATED T-CELL

ANTIGEN

Examiner: Not yet assigned

Date: April 15, 2002

CERTIFICATE OF MAIL INTECH CENTER 1600/2900

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 17, 2002 as First Class Mail in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C.

Sheree Lynn Rybak, Ph.

Agent for Applicants

REVOCATION OF PRIOR POWER OF ATTORNEY, NEW POWER OF ATTORNEY BY ASSIGNEE AND CERTIFICATE BY ASSIGNEE UNDER 37 CFR § 3.73

COMMISSIONER FOR PATENTS WASHINGTON D.C. 20231

THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES is the Assignee of the entire right, title and interest in the above-identified patent application, as evidenced by the Assignment

x attached hereto.

recorded in the U.S. Patent and Trademark Office at Reel, Frame(s)

The Assignee hereby revokes all prior powers of attorney for this matter, and appoints as its representatives to conduct all business in the Patent and Trademark Office connected therewith the attorneys and agents identified below:

Name	Reg. No.	Name	Reg. No.
James C. Haight	25,588	Jack Spiegel	34,477
Robert Benson	33,612	David R. Sadowski	32,808
Susan S. Rucker	35,762	Steve Ferguson	38,448
John Peter Kim	38,514	Richard U. Rodriguez	45,980
Stephen L. Finley	36,357	Marlene Shinn	46,005
Norbert Pontzer	40,777		

all of the National Institutes of Health, Office of Technology Transfer, 6011 Executive, Boulevard, Suite #325, Rockville, MD 20852; and grants an Associate Power of Attorney to the attorneys and agents listed below:

Wayne W. Rupert

Devon J. Zastrow

Gillian Bunker

34,420

47,461

P-50,206

Reg. No. Name Reg. No. Name 28,107 Lisa M. Caldwell 41,653 Richard J. Polley 41,879 William D. Noonan 30,878 Michael D. Jones Donald L. Stephens Jr. 34,022 Tanya M. Harding 42,630 Gregory L. Maurer Stacey C. Slater 36,011 43,781 Susan Alpert Siegel Robert F. Scotti 39,830 43,121

all of the law firm of Klarquist Sparkman, LLP, 121 SW Salmon Street, Suite 1600, Portland, Oregon 97204.

Sheree L. Rybak

Anne Carlson

47,913

47,472

The Assignee certifies that the above-identified Assignment has been reviewed and to the best of Assignee's knowledge and belief, title is in the Assignee, as demonstrated by the copy of the Assignment submitted herewith.

Please address all correspondence to William D. Noonan, M.D. at:

KLAROUIST SPARKMAN, LLP One World Trade Center, Suite 1600 121 SW Salmon Street Portland, OR 97204-2988 Telephone: 503-226-7391

Fax: 503-228-9446

The National Institutes of Health Office of Technology Transfer has been duly delegated responsibility for patent matters under the authority of the memorandum dated May 21, 1991, from Louis W. Sullivan, the Secretary of the Department of Health and Human Services, delegating the authority to the Heads of the Public Health Service Operating Divisions, as well as a memorandum dated October 9, 2001, from Mark L. Rohrbaugh, Ph.D., J.D., Acting Director, Office of Technology Transfer, National Institutes of Health, delegating authority to sign this Power of Attorney to the undersigned individual. The undersigned is therefore authorized to exercise such authority in this matter.

Executed on 10 may 2002, at Rockville, Maryland.

UNITED STATES DEPARTMENT OF **HEALTH AND HUMAN SERVICES**

Name: SUSAN RUCICER

Reg. No.:

35 762 National Institutes of Health

Office of Technology Transfer

6011 Executive Boulevard, Suite #325

Rockville, MD 20852

ASSIGNMENT

WHEREAS, we, Ken-Ichi Hanada, of 10101 Grosvenor Place, #1209, Rockville, MD 20852, a citizen of Japan, and James C. Yang, of 1 Serpentine Ct., Silver Spring, MD 20904, a citizen of the United States of America, employees of the Department of Health and Human Services at the time the invention was made, have invented FIBROBLAST GROWTH FACTOR-5 (FGF-5) IS A TUMOR ASSOCIATED T-CELL ANTIGEN for which the following patent applications have been filed:

U.S.	Provisional	Patent Application No.	60/157,103, filed or	n October 2, 1999;	
PCT	Application	No. PCT/US00/26689 f	filed on September	29, 2000; and	
U.S.	Application	No	filed on		•

all three of which applications are collectively referred to herein as "the patent applications."

WHEREAS, the conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive order 10096, to the entire right, title, and interest, both domestic and foreign, of the invention and patent applications; and

WHEREAS, the Government of the United States of America is desirous of acquiring all domestic and foreign right, title, and interest in the aforesaid invention described in the aforesaid patent applications as well as any Letters Patent of the United States of America issuing therefrom; and

NOW, THEREFORE, to all whom it may concern, be it known for and in consideration of the premises and other valuable considerations, we the undersigned, have sold, assigned, and transferred and by these presents do sell. assign, and transfer unto The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (hereinafter THE GOVERNMENT), and their successors, the full and exclusive right, title, and interest in the invention, patent applications and patent rights throughout the United States of America, its territories and dependencies, and within each and every foreign country in which THE GOVERNMENT elects to file the invention described in the aforesaid patent applications, all rights in the invention and the patent applications, and all Letters Patents and Registrations which may be granted on the same in the United States of America and all countries throughout the world, and to claim the priority from the patent applications as provided by United States law and the Paris Convention, or of any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

AND, we hereby authorize and request the Commissioner for Patents to issue said Letters Patent or Patents to THE GOVERNMENT as an assignee of the entire right, title, and interest in and to the same throughout the United States of America, its territories and dependencies, and within each and every foreign country in which THE GOVERNMENT elects to file, for the sole use for the full term or terms for which said Letters Patent or Patents and Registrations may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof which may be granted as fully and entirely as the same would have been held by us, had this assignment not been made;

AND, we hereby warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied with respect to the aforesaid patent applications which will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of this instrument by us;

AND, we hereby agree to execute any and all applications for Letters Patent in the United States of America and foreign countries, and to furnish and deliver to the Secretary, Department of Health and Human Services, upon request, all data and documents, and to execute any papers which may be necessary for the prosecution of any application or applications of Letters Patent or for THE GOVERNMENT to exercise its rights granted hereunder, including communicating to THE GOVERNMENT, its representatives or agents, any facts relating to said invention.

including evidence for interference purposes, or for other proceedings, whenever requested, to testify in any interference or other proceedings, whenever requested, and to execute and deliver on request all lawful papers required to make any of the foregoing provisions effective, and likewise make these provisions binding upon our heirs, legal representatives, administrators and assigns, and we shall assist THE GOVERNMENT in every way as may be requested in protecting said invention, provided that any expense of extending such assistance shall be paid by THE GOVERNMENT.

we hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information which may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated:	3/	19/	02.
--------	----	-----	-----

Cen ichi Hanada

, 2002, before me personally came the above-named Ken-Ichi Hanada, who executed the foregoing Assignment in my presence, and who acknowledged to me that he executed the same of his own free will for the purposes set forth therein.

My commission AND TON MISSION EXPIRES

MARCH 1, 2003 MARGARET L. TOMCZAK NOTARY PUBLIC

[SEAL]

7) Thuck , 2002, before me personally came the above-named James C. Yang. who executed the foregoing Assignment in my presence, and who acknowledged to me that he executed the same of his own free will for the purposes set forth therein.

MY COMMISSION EXPIRES MARCH 1, 2003 MARGARET L. TOMCZAK NOTARY PUBLIC

ISEAL